May 1st 2024
April brought 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Not So Different: What the Generics Industry Can Tell Us About the Future of Biosimilars
July 18th 2021On this week’s episode of Not So Different, we spoke with David Senior, senior vice president of Market Economics at AmerisourceBergen, about the development of the generics market and how this could be instructive in understanding how biosimilars sales may develop.
Gan & Lee Insulin Biosimilar Candidates Demonstrate Biosimilarity in Trials
July 6th 2021Insulin aspart, lispro, and glargine biosimilar candidates referencing NovoRapid, Humalog, and Lantus demonstrated bioequivalence in trial data presented at the Scientific Sessions of the American Diabetes Association.